ArticleCancer immunology, immunotherapy : CII2022

Combined treatment with anti-HER2/neu and anti-4-1BB monoclonal antibodies induces a synergistic antitumor effect but requires dose optimization to maintain immune memory for protection from lethal rechallenge.

Hee Yeon Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.